Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Shares Climb 5.4 Percent on Strong Q4, Flu Deal, Stock Upgrade

NEW YORK, March 1 (GenomeWeb News) - Shares in Invitrogen were up $3.85, or 5.43 percent, at $74.78 in afternoon trade after the company reported strong fourth-quarter earnings, disclosed a deal to help develop a process for incorporating an avian H5 influenza antigen, and was upgraded by an investment bank.


Leerink Swann upgraded Invtrogen's stock to 'Outperform' from 'Market Perform' today.


Under the flu agreement, drug maker DelSite will use Invitrogen's PD-Direct platform to develop large-scale cGMP production of the vaccine.


Financial details of the deal were not released.


DelSite received a $6-million, three year biodefense grant from NIAID in December 2004.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.